Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Chronic heart failure

- PMLiVE

Biotecnol taps into Cancer Research UK network for first trial

New drug hoped to have broad activity across multiple tumour types

- PMLiVE

Bayer’s Nexavar backed by NICE for liver cancer

The drug is the only approved first-line treatment for advanced HCC

Bayer symbol

EMA clears Bayer’s Stivarga for liver cancer

The multikinase inhibitor will treat patients with HCC

AstraZeneca AZ

Shock for AZ as MYSTIC trial stumbles at first hurdle

Combination fails to improve progression-free survival for lung cancer patients

- PMLiVE

Novartis and Bayer among backers for European big data project

The IMI's BigData@Heart programme will target cardiovascular research

- PMLiVE

Merck & Co’s Remicade biosimilar undercuts its US rivals

Its version will be 35% cheaper than J&J's originator product

Bayer symbol

Bayer moves vilaprisan into phase III trials for uterine fibroids

ASTEROID study will investigate safety and efficacy of the novel drug

- PMLiVE

FDA halts third Merck myeloma trial after patient deaths

More patients died on Keytruda combination than those on other treatments

Bayer symbol

Bayer wins FDA approval for MS electronic autoinjector and app

US regulator gives green light to Betaconnect and myBETA app

- PMLiVE

MSD probed by UK for blocking Remicade biosimilars

Pharma giant’s discount scheme for infliximab labelled ‘anti-competitive’

- PMLiVE

Keytruda is first FDA-approved drug for molecular indication

Indicates a significant development in the shift towards personalised medicine

- PMLiVE

Merck says Afferent’s chronic cough drug clears mid-stage trial

MK-7264 reduces coughs per hour by 37%

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links